NASOPHARYNGEAL CANCINOMA (NPC)

This study tests whether adding a targeted drug (Becotatug Vedotin) to standard immunotherapy and chemo-radiation can better shrink or control high-risk nasopharyngeal cancer. About 514 adults with advanced throat cancer will be randomly assigned to receive either the new combo o…

This study tests two drugs, Becotatug vedotin and Pucotenlimab, as a first treatment for people whose nasopharyngeal cancer has come back or spread. About 30 adults aged 18-75 with advanced disease will receive the combination. The goal is to see if it slows cancer growth and is …

This study compares a shorter versus longer course of the immunotherapy drug tislelizumab, given alongside standard chemoradiotherapy, for people with advanced nasopharyngeal cancer. About 418 adults aged 18 to 65 with stage T4N1 or T1-4N2-3 disease will be randomly assigned to r…

This phase 3 trial tests whether adding anlotinib (a targeted therapy) to standard chemoradiotherapy and immunotherapy can improve outcomes for people with high-risk nasopharyngeal cancer. About 412 adults aged 18-65 with advanced, non-spreading throat cancer will be randomly ass…

This study is for people whose nasopharyngeal cancer has come back and cannot be surgically removed. It tests a treatment plan that starts with a mix of an immunotherapy drug (PD-1 antibody) and two chemotherapy drugs, followed by targeted radiation. The goal is to see if this ap…

This phase 3 trial tests whether adding chemotherapy to immunotherapy can better control advanced nasopharyngeal cancer in patients who still have signs of the virus (EBV DNA) after initial treatment. About 516 adults with stage II–III disease will receive either immunotherapy al…

This study tests whether giving immunotherapy (pembrolizumab) plus chemotherapy before and after surgery can improve outcomes for people whose nasopharyngeal cancer has returned locally. About 53 adults with recurrent cancer that hasn't spread will receive the drug combo, then un…